Bruker (NASDAQ:BRKR) Stock Price Up 6.9% – What’s Next?

Bruker Corporation (NASDAQ:BRKR) shares rose 6.9% during trading on Wednesday . The stock traded as high as $61.10 and last traded at $61.2830. Approximately 1,753,429 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 2,395,581 shares. The stock had previously closed at $57.31.

Analyst Ratings Changes

BRKR has been the subject of several recent analyst reports. Barclays raised their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wolfe Research initiated coverage on shares of Bruker in a report on Monday. They issued a “peer perform” rating for the company. UBS Group raised their target price on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Bruker in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $50.54.

Bruker Stock Performance

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm has a market capitalization of $9.13 billion, a price-to-earnings ratio of -249.88, a PEG ratio of 2.01 and a beta of 1.31. The firm’s fifty day moving average is $42.16 and its 200 day moving average is $43.36.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 27.20% of the stock is owned by company insiders.

Institutional Trading of Bruker

A number of institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in Bruker by 5,291.2% in the first quarter. NewEdge Advisors LLC now owns 1,833 shares of the medical research company’s stock valued at $66,000 after acquiring an additional 1,799 shares during the last quarter. Essential Partners LLC acquired a new stake in Bruker in the first quarter valued at approximately $36,000. Groupe la Francaise acquired a new stake in Bruker in the first quarter valued at approximately $1,222,000. Liontrust Investment Partners LLP lifted its stake in Bruker by 113.3% in the first quarter. Liontrust Investment Partners LLP now owns 3,844 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 2,042 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Bruker by 2.1% in the first quarter. Janus Henderson Group PLC now owns 100,380 shares of the medical research company’s stock valued at $3,625,000 after acquiring an additional 2,090 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.